Academic publications


  • Arbyn M, Gultekin M, Morice P, Nieminen P, Cruickshank M, Poortmans P, Kelly D, Poljak M, Bergeron C, Ritchie D, Schmidt D, Kyrgiou M, Van den Bruel A, Bruni L, Basu P, Bray F, Weiderpass E. The European response to the WHO call to eliminate cervical cancer as a public health problem. Int J Cancer. 2021 Jan 15;148(2):277-284. doi: 10.1002/ijc.33189.


  • Inturrisi F, Bogaards JA, Heideman DAM, Meijer CJLM, Berkhof J. Risk of cervical intraepithelial neoplasia grade 3 or worse in HPV-positive women with normal cytology and five-year type concordance: a randomized comparison. Cancer Epidemiol Biomarkers Prev 2020 Dec 8 doi:10.1158/1055-9965.EPI-20-1336
  • Robles C, Bruni L, Acera A, Riera JC, Prats L, Poljak M, Mlakar J, Ostrbenk Valencak A, Eriksson T, Lethinen M, Louvanto K, Hortlund M, Dillner J, Faber MT, Munk C, Kjaer SK, Petry KU, Denecke A, Xu L, Arbyn M, Cadman L, Cuzick J, Dalstein V, Clavel C, de Sanjosé S, Bosch FX. Determinants of Human Papillomavirus Uptake by Adult Women Attending Cervical Cancer Screening in 9 European Countries. Am J Prev Med 2020 Dec 24;S0749-3797(20)30434-7. doi: 10.1016/j.amepre.2020.08.032.
  • Tagliabue M, Mena M, Maffini F, Gheit T, Quirós Blasco B, Holzinger D, Tous S, Scelsi D, Riva D, Grosso E, Chu F, Lucas E, Ridder R, Rrehm S, Bogers JP, Lepanto D, Lloveras Rubio B, Kumar RV, Gangane N, Clabero O, Pawlita M, Anantharaman D, Pillai MR, Brennan P, Sankaranarayanan R, Arbyn M, Lombardi F, Taberna M, Gandini S, Chiesa F, Ansarin M, Alemany L, Tommasino M, Chiocca S and the HPV-AHEAD Study Group. Role of Human Papillomavirus Infection in Head and Neck Cancer in Italy: The HPV-AHEAD Study. Cancers 2020, 12(12), 3567;
  • Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, Kim J, Poljak M, Nieminen P, Sasieni P, Kesic V, Cuzick J, Gultekin M. Cervical screening: ESGO- EFC position paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer. 2020 Aug;123(4):510-517. doi: 10.1038/s41416-020-0920-9.
  • Arbyn M, Bruni L, Kelly D, Basu P, Poljak M, Gultekin M, Bergeron C, Ritchie D, Weiderpass E. ‘Tackling Cervical Cancer in Europe amidst the COVID-19 Pandemic’. The Lancet Public Health 5, no. 8 (1 August 2020): e425.
  • Louvanto K, Eriksson T, Gray P, Apter D, Baussano I, Bly A, Harjula K, Heikkila K, Hokkanen M, Huhtinen L, Ikonen M, Karttunen H, Nummela M, Söderlund-Strand A, Veivo U, Dillner J, Elfstöm M, Nieminen P, Lehtinen M. Baseline findings and safety of of infrequent of frequent screening of human papillomavirus vaccinated women. International Journal of Cancer. 2020 Jul 15;147(2):440-447. doi: 10.1002/ijc.32802.
  • Bray F, Laversanne M, Weiderpass E, Arbyn M. ‘Geographic and Temporal Variations in the Incidence of Vulvar and Vaginal Cancers’. International Journal of Cancer 147, no. 10 (2020): 2764–71.
  • Arbyn M, Gondry J, Nieminen P. Long-term prediction of failure after treatment of cervical precancer. BJOG. 2020 Feb;127(3):388. doi: 10.1111/1471-0528.16023.
  • Ciavattini A, Delli Carpini G, Giannella L, Arbyn M, Kyrgiou M, Joura EA, Sehouli J, Carcopino X, Redman CW, Nieminen P, Cruickshank M, Gultekin M. European Federation for Colposcopy (EFC) and European Society of Gynaecological Oncology (ESGO) joint considerations about human papillomavirus (HPV) vaccination, screening programs, colposcopy, and surgery during and after the COVID-19 pandemic. Int J Gynecol Cancer. 2020 Aug;30(8):1097-1100. doi: 10.1136/ijgc-2020-001617.
  • Inturrisi F, Lissenberg-Witte BI, Veldhuijzen NJ, Bogaards JA, Ronco G, Meijer CJLM, Berkhof J. Estimating the direct effect of human papillomavirus vaccination on the lifetime risk of screen-detected cervical precancer. Int J Cancer. 2020 Jul 14. doi: 10.1002/ijc.33207.
  • Arbyn M, Rezhake R, Yuill S, Canfell K. Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence. Br J Cancer. 2020 May;122(11):1577-1579. doi: 10.1038/s41416-020-0787-9.
  • Ejegod, Ditte Møller, Mona Hansen, Irene Kraus Christiansen, Helle Pedersen, Wim Quint, Lan Xu, Marc Arbyn, and Jesper Bonde. ‘Clinical Validation of the Cobas 4800 HPV Assay Using Cervical Samples in SurePath Medium under the VALGENT4 Framework’. Journal of Clinical Virology 128 (1 July 2020): 104336.
  • Peeters E, Cornet K, Devroey D, Arbyn M. ‘Efficacy of Strategies to Increase Participation in Cervical Cancer Screening: GPs Offering Self-Sampling Kits for HPV Testing versus Recommendations to Have a Pap Smear Taken - A Randomised Controlled Trial’. Papillomavirus Research 9. Corrigendum: doi: 10.1016/j.pvr.2020.100201
  • Xu L, Ostrbenk Valencak A, Poljak M, Arbyn M. Evalaution and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16/18 Genotyping Assay within the VALGENT-3 framework. J Clin Microbiol 2020 May 26;58(6):e00234-20. doi: 10.1128/JCM.00234-20.
  • Urbute A, Rasmussen CL, Belmonte F, Obermueller T, Prigge E, Arbyn M, Verdoodt F, Kjaer S. Prognostic Significance of HPV DNA and p16 INK4a in Anal Cancer: A Systematic Review and Meta-Analysis. Cancer Epidemiol Biomarkers Prev 2020 Apr;29(4):703-710. doi: 10.1158/1055-9965.EPI-19-1259.
  • Poljak M, Oštrbenk Valenčak A, Gimpelj Domjanič G, Xu L, Arbyn M. ‘Commercially Available Molecular Tests for Human Papillomaviruses: A Global Overview’. Clinical Microbiology and Infection, 2 April 2020.
  • Rezhake R, Chen F, Hu S, Zhao X, Zhang X, Cao J, Qiao Y, Zhao F, Arbyn M. ‘Triage Options to Manage High-Risk Human Papillomavirus-Positive Women: A Population-Based Cross-Sectional Study from Rural China’. International Journal of Cancer 147, no. 8 (2020): 2053–64.
  • Nowakowski A, Arbyn M, Turkot MH, Wieszczy P, Milosz K, Kaminski M, Didkowska J, Bidzinski M, Oleszewski W, Wielgos M, Krzakowski M, Kuchar E, Walewski J. A roadmap for a comprehensive control of cervical cancer in Poland: integration of available solutions into current practice in primary and secondary prevention. Eur J Cancer Prev 2020 Mar;29(2):157-164. doi: 10.1097/CEJ.0000000000000528.
  • Kalliala I, Athanasiou A, Veroniki AA, Galanti G, Efthimiou O, Raftis N, Bowden S, Paraskevaidi M, Aro K, Arbyn M, Bennet P, Nieminen P, Parakevaidis E, Kyrgiou M. Incidence and mortality from cervical cancer and other malignancies after treatment of cervical intraepithelial neoplasia: a systematic review and meta-analysis of the literature. Ann Oncol 2020 Feb;31(2):213-227. doi: 10.1016/j.annonc.2019.11.004.
  • Arbyn M, Weiderpass E, Bruni L, de Sanjosé, Saraiya M, Ferlay J, Bray F. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. Lancet Glob Health 2020 Feb;8(2):e191-e203. doi: 10.1016/S2214-109X(19)30482-6.
  • Bonde JH, Pedersen H, Quint W, Xu L, Arbyn M, Ejegod DM. Clinical and Analytical Performance of the BC Onclarity HPV assay with SurePath Screening Samples from the Danish Cervical Screening Program Using the VALGENT Framework. J Clin Microbiol . 2020 Jan 28;58(2):e01518-19. doi: 10.1128/JCM.01518-19.
  • Weyers S, Garland SM, Cruickshank M, Kyrgiou M, Arbyn M. ‘Cervical Cancer Prevention in Transgender Men: A Review’. BJOG: An International Journal of Obstetrics & Gynaecology (2020).

Other publications